



# Androgen Society


The Androgen Society 5th Annual Meeting

## PROGRAM **BOOK**

**MARCH 2-4, 2023**

**Marriott Dallas Downtown  
Dallas, Texas**

President Hugh Jones, MD, welcomes you to  
the Androgen Society 5th Annual Meeting.



# Do you know about AReA?

AReA — the Andrology Research Academy — is a free medical education platform that offers a forum for the exchange of scientific information on the latest research and cutting-edge topics in the field of andrology.




Check it out at <https://live.arealive.org> and attend the next AReA symposium on 3 March, here at the 5th Annual Meeting of the Andrology Society.

## Improving Clinical Practice with Testosterone: Data from the TestES Consortium

Friday 3 March 2023 at 12:00 US Central Time (18:00 GMT)



**Dr. Janine David (UK)**  
Moderator



**Dr. Channa Jayasena (UK)**  
Speaker

AReA is a non-promotional platform sponsored by BESINS Healthcare as part of the company's commitment to continuous medical education, ensuring that physicians have the most up-to-date knowledge to make the best treatment choices for their patients.

# Androgen Society

March 2-4, 2023 | Marriott Dallas Downtown | Dallas, Texas

## General Meeting Information

### Thursday, March 2, 2023

---

#### Registration/Information Desk

4:30 p.m. - 6:30 p.m.

*Location: Cedars/Pegasus/Whiterock Foyer*

### Friday, March 3, 2023

---

#### Registration/Information Desk

6:00 a.m. - 6:00 p.m.

*Location: Cedars/Pegasus/Whiterock Foyer*

#### Exhibit Hall

7:00 a.m. - 4:00 p.m.

6:00 p.m. - 8:00 p.m. (Welcome Reception)

*Location: Plaza C*

### Saturday, March 4, 2023

---

#### Registration/Information Desk

6:00 a.m. - 5:00 p.m.

*Location: Cedars/Pegasus/Whiterock Foyer*

#### Exhibit Hall

7:00 a.m. - 3:00 p.m.

*Location: Plaza C*

## Table of Contents

Welcome Message	2
Board of Directors	2
CME Information	3
Scientific Program	6
Speaker Biosketches	10
Abstracts	10
Satellite Symposium	11
Notes	11
Industry Support	12
Exhibit Hall Floor Plan	13

# Welcome Message



## Dear Colleagues and Friends,

It is a great privilege to welcome you all here to the 5th Annual Meeting of the Androgen Society in Dallas.

This year we have again provided a program which has included a wide range of clinical and scientific areas. There is a special focus on the role of Testosterone in Immunity including a lecture on COVID-19. We have some excellent speakers providing us with their knowledge and experience in practical management and up to date research findings of men and women with androgen deficiency.

There is a clear unmet need of the knowledge, diagnosis and treatment of Testosterone Deficiency in the world with very many people being undiagnosed and suffering as a result of the chronic effects of this condition.

The Androgen Society was formed to provide a forum which includes all health professionals from any clinical or scientific specialty to learn, discuss and give up to date, original research in the field of androgens, especially testosterone deficiency and its management in men and women.

The meeting this year commences on the Thursday evening with a Welcome and Keynote Lecture on "This is Your Brain on Androgens." Afterwards, there is time to network and meet up with other attendees. This is followed by two full days of talks from experts from different disciplines in medicine. These include Men's Health, Women's Health, Andrology, Obesity, Diabetes, Endocrinology, Cardiology, Hematology, Immunology, COVID, Neurology, Oncology, Primary Care, Fertility, Gynecology, and Urology.

Highlights of this meeting include lectures on the role of testosterone in Men's Health, Diabetes, Anemia, Cardiovascular disease and Prostate Cancer. The immune system has a key role in many human diseases. Testosterone has an important beneficial action in the immune response which are not well known by the many in the medical community. There is a session on 'Assessment of T' including views on harmonisation of assays. There will be an updates on the important clinical area of testosterone therapy safety and testosterone therapy.

The Annual Meeting provides an exciting educational and up to date meeting with new scientific and clinical research presentations including oral and poster communications in a broad and extensive program. The program provides us with information on specific areas related to androgens which I believe will be of interest to you from an educational perspective, and it will provide new data from recent research. I hope you will attend the meeting and join with specialists and colleagues for what I feel will be a unique learning experience.

I wish to sincerely thank you all for joining us here in Dallas and making this a truly unique and memorable meeting.

Hugh Jones, MD, FRCP(London), FRCP(Edinburgh)  
*Androgen Society President*

# Board of Directors

## OFFICERS

### President

Hugh Jones, MD

### Vice President

Abdulmageed M. Traish, MBA, PhD

### Treasurer

Martin Miner, MD

### Secretary

Michael Zitzmann, MD, PhD, FRSM

### Immediate Past President

Abraham Morgentaler, MD, FACS

### Board Representative

Adrian S. Dobs, MD, MHS

## Program Chair

Michael Zitzmann, MD, PhD, FRSM

## EXECUTIVE OFFICE

### Executive Director

Heather Swanson

### Associate Director

Brittany Beissel

### ANDRO Executive Office

1100 E. Woodfield Road, Suite 350

Schaumburg, IL 60173

Phone: (847) 517-7225

Fax: (847) 517-7229

[androgensociety@wjweiser.com](mailto:androgensociety@wjweiser.com)

# CME Information

## EDUCATIONAL NEEDS

Peripheral and central androgen therapies are used in the treatment of sexual arousal and desire disorders, although mostly off-label and without concrete knowledge of their mechanism(s) of action. Unfortunately, androgen therapies have been laden with misunderstanding and misinformation, making clinicians suspicious of their efficacy. Empirical studies of androgen actions in the brain and periphery on sexual functions will help dispel myths and show the promise of these agents for the treatment of sexual arousal, desire, and possibly orgasm disorders in both males and females.

There are still significant controversies about the diagnosis and etiology of male hypogonadism, leading to confusion by both patients and providers. It is challenging to make sense of the various assays used in making the diagnosis and to determine the appropriate workup. The signs and symptoms of hypogonadism can be non-specific, and the risks and benefits of testosterone therapy are still controversial.

Women are the traditional health brokers for children and men in the family. Men often delay medical attention until conditions become advanced. Many medical conditions can be treated at an earlier stage to prevent the onset of common urological/andrological conditions (e.g., hypogonadism, erectile dysfunction, and infertility) from progressing.

Men who are overweight or obese frequently have low serum testosterone concentrations, which are associated with increased risk of type 2 diabetes. In the absence of obesity, adverse lifestyle behaviors, and use of medication such as serum testosterone concentrations decrease by only a minimal amount at least until very advanced age in most men.

Anemia is very common especially in women and in elderly men. Often it is a finding of a routine blood examination. Beside causing anemia low T levels can also cause other diseases with a high impact on the quality of life of the subjects.

The effect of TRT on QoL in cohort of patients who have both hypogonadism and T2DM is poorly understood. There are only a handful of RCTs who have looked at the effect of testosterone on sexual and constitutional symptoms in diabetes population. Our recent study will be the first study to show significant clinical improvement in the symptoms as measured by total AMS scores in a cohort with both hypogonadism and type 2 diabetes. This result will hence have significant clinical implication in patients with diabetes who have hypogonadism and makes an argument to actively diagnose and institute treatment in these patients to better their clinical symptoms.

Borderline low testosterone levels are commonly seen in older men and those with comorbidities such as overweight/obesity, diabetes and depression. Several contraindications to testosterone therapy have also been based upon limited data. Clinicians need to

be aware of the potential clinical scenarios where testosterone therapy may be considered, potential benefits and potential adverse effects/risks.

Testosterone deficiency has been shown to occur in up to 74% of men taking long-action opioid medication for CNCP. We need to increase awareness of OPIAD and to educate physicians on strategies to identify and manage this syndrome effectively. Physicians need to be aware of how common a deficiency in testosterone and associated symptoms can be in patients using opioid medication for CNCP so that they can take appropriate steps to improve the care of these patients.

The accuracy and reliability of testosterone tests can differ among test manufacturers and laboratories. Urologists need to be aware of the analytical accuracy and reliability of these tests when using them together with clinical practice guidelines and recommendations.

There is confusion as to what serum level of testosterone is consistent with hypogonadism. Because the diagnosis of hypogonadism requires laboratory confirmation of a low level of testosterone, clinicians rely heavily on laboratory reference ranges to determine whether a patient may be a candidate for TRT. However, a wide variety of testosterone assays are in use with varying reference ranges. Healthcare providers need to be knowledgeable about how various testosterone blood tests are performed and how to apply results to clinical practice.

Hormone imbalance for men and women creates significant morbidity and mortality. There is clear evidence that T promotes well-being in both sexes. There is no other drug that does this. Because of a multitude of factors it is frequently ignored, leading many to suffer. Providers should be aware of the enormous amount of hormone data, leaving no single study to be the defining study.

A review of the biochemical evidence indicating that testosterone has immunological actions in the pathogenesis of Covid-19 through modification of SARS-CoV-2 infection pathways, inflammatory response and immune recovery is needed in the field of andrology.

# CME Information

## EDUCATIONAL OBJECTIVES

At the conclusion of the Androgen Society's 5th Annual Meeting, attendees will be able to:

1. Explain the role of androgens as signaling molecules for diverse biological functions.
2. Explain in detail the mechanisms of action of androgens on androgen receptors in brain and periphery.
3. Review androgen's effects on sexual dysfunctions, particularly sexual arousal and desire disorders in both men and women.
4. Dispel the myth of androgens as "male" hormones.
5. Review how androgen affects in the periphery link up with those in the brain.
6. Identify issues relating to increased male mortality.
7. Identify gaps to improve male cardiometabolic health in the disease states of obesity and sleep.
8. Identify new treatments for obesity that improve ASCVD risk and lower renal disease.
9. Explain the actions and therapeutic benefits of Glucagon-Like Peptide Agonists (GLP-1 agonists) in the treatment of obesity.
10. Identify the improvements in mortality associated with the STEP studies of semaglutide.
11. Identify possible improvements of male mortality with the treatments for erectile dysfunction and the use of PDE5 inhibitors.
12. Identify improvements of ED with lifestyle therapies and the association of ED with ASCVD risk.
13. Discuss the myriad options of testosterone treatment and how to determine the optimal form for patients.
14. Review the various guidelines of key medical societies.
15. Discuss the similarities and differences across the various recommendations.
16. Discuss the importance of a more patient-oriented approach to the diagnosis of treatment of male hypogonadism.
17. Demonstrate that prevention measures and early treatment of many medical conditions can prevent the onset of common urological/andrological afflictions (e.g., sexual dysfunction, hypogonadism, male factor infertility).
18. Educate and transmit the concept that young men need to take charge of their medical care at an early age after leaving the family.
19. Identify common comorbidities and their respective treatments (e.g., diabetes, cardiovascular disease, hypertension, dyslipidemia, obesity, etc.) that in turn may prevent the onset of medical pathologies (hypogonadism, sexual dysfunction, infertility).
20. Discuss the T4DM study regarding testosterone and diabetes care.
21. Discuss new clinical developments in the field of androgens.
22. Review Andrology and relationship with other specialties.
23. Review symptoms and assess biochemical testing for male hypogonadism to determine the best course of treatment.
24. Discuss the advantages and disadvantages of routine blood analysis.
25. Discuss the indications and potential benefits of TRT in anemia patients.
26. List options for medical therapy of TRT and their potential long term side effects.
27. Discuss the new data regarding testosterone therapy and how it may affect hematocrit levels.
28. Discuss the effect of testosterone deficiency on quality of life in patients with hypogonadism and Type 2 Diabetes.
29. Discuss the effects of Testosterone replacement therapy on the symptom severity.
30. Review the results of the RCT (STRIDE STUDY) showing the positive effects of Testosterone therapy on QoL in patients with hypogonadism and type 2 diabetes.
31. Review the evidence around TRT and its safety.
32. Review the role of testosterone and PDE5 inhibitors for the reduction of acute and chronic complications.
33. Discuss controversial issues around acute COVID-19 infection with reference to personal near fatal experience.
34. Review the evidence base for the new 2023 BSSM Guidelines recently accepted by the World Journal of Men's Health.
35. Define functional hypogonadism.
36. Discuss potential benefits of testosterone therapy for male hypogonadism.
37. Discuss potential risks of testosterone therapy for male hypogonadism.
38. Describe testosterone's effect on prostate cancer growth.
39. Discuss Bipolar Androgen Therapy (BAT) and the latest trials using BAT to treat prostate cancer.
40. Explain the relationship between testosterone and cardiovascular risk.
41. Review the TRAVERSE Trial and the rationale behind initiating the trial.
42. Recognize the prevalence of CNCP and opioid use.
43. Discuss the history of opioids and opioid use and the prevalence of OPIAD.
44. Discuss the clinical consequences of OPIAD.
45. Identify strategies to effectively manage OPIAD.
46. Review the association of testosterone and estrogen in patients with acute COVID-19.
47. Review the association of male hypogonadism with risk of hospitalization from COVID-19.
48. Review the effect of testosterone therapy on risk of hospitalization from COVID-19.
49. Discuss the various methodologies being used for Total Testosterone testing.
50. Review methods and quality of the Free Testosterone Test.
51. Review methods and quality of the Bioavailable Testosterone Test.
52. Discuss the analytical performance of testosterone assays.
53. Describe the CDC Clinical Standardization Program for testosterone.
54. Discuss activities conducted by CDC to improve testosterone testing and data.
55. Discuss resources available to identify standardized testosterone tests and laboratories.
56. Discuss how various testosterone blood tests are performed and how to apply results to clinical practice.
57. Describe the workup to diagnose hypoactive sexual desire disorder.
58. Discuss proper dosing of testosterone in post-menopausal women.
59. Describe testosterone use for pelvic pain and vestibulodynia conditions.
60. Review the organ systems that are clinically most affected by T deficiency/insufficiency and discuss the clinical outcomes with adequate replacement.
61. Review the biochemical evidence indicating that testosterone has immunological actions in the pathogenesis of Covid-19 through modification of SARS-CoV-2 infection pathways, inflammatory response and immune recovery.



# CME Information

## Accreditation Statement

### SAPS CME ACCREDITATION STATEMENT:

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Medical Association of Georgia through the joint providership of the Southern Alliance for Physician Specialties CME and the Androgen Society. The Southern Alliance for Physician Specialties CME is accredited by the Medical Association of Georgia to provide continuing medical education for physicians.

The Southern Alliance for Physician Specialties CME designates this live activity for a maximum of **15.25 AMA PRA Category 1 Credits™**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Non-physician healthcare professionals will receive a Certificate of Attendance. For information on the applicability and acceptance of Certificates of Attendance for educational activities certified for *AMA PRA Category 1 Credit™* from organizations accredited by the ACCME, please consult your professional licensing board.

## General Disclaimer

The statements and opinions contained in this program are solely those of the individual authors and contributors and not of the Androgen Society. The appearance of the advertisements is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality, or safety. The content of this publication may contain discussion of off-label uses of some of the agents mentioned. Please consult the prescribing information for full disclosure of approved uses. The Androgen Society disclaims responsibility for any injury to persons or property resulting from any ideas or products referred to in the abstracts or advertisements.

## Special Assistance

We encourage participation by all individuals. If you have a disability, advance notification of any special needs will help us better serve you. Call (847) 517-7225 if you require special assistance to fully participate in the meeting.

## Disclosure Report

The disclosure report for the Androgen Society 5th Annual Meeting can be found online at:

[virtual.association-service.org/docs/as/disclosures.aspx](http://virtual.association-service.org/docs/as/disclosures.aspx)



## How to Claim CME

*Please note the electronic CME submission form will open Saturday, March 4 at 8:00 a.m. Central and close on Sunday, March 26 at 11:59 p.m. Central Time.*



The CME submission form may be accessed via the link below or the QR code to the left.

[virtual.association-service.org/as/cme](http://virtual.association-service.org/as/cme)

- 1. Record your attendance.** Attendees should claim only credit commensurate with the extent of their participation in the activity. When complete, click the "Submit CME Time Claimed" button.
- 2. Complete Evaluation.** Approximately 4 weeks post-meeting, you will receive an email with a link to the CME Evaluation Survey. Follow the link to complete the survey online. The CME Evaluation will be open for 60 days.
- 3. Access your Certificate.** Immediately following completion of the CME Evaluation Survey, you will be redirected to the certificate site. Once you sign-in you will have access to your CME or Participation Certificate.

For physicians to officially receive *AMA PRA Category 1 Credit™* and for other healthcare providers to document their attendance, participants are required to complete both this attendance worksheet and the activity evaluation online.

Attendance and evaluations will be tracked.

If you have difficulties with the online CME submission, you may contact us via email at [cmeinfo@wjweiser.com](mailto:cmeinfo@wjweiser.com) or via phone during regular business hours at (847) 517-7225.

# Scientific Program

All sessions will be located in Plaza AB unless otherwise noted.

## THURSDAY, MARCH 02, 2023

### OVERVIEW

4:30 p.m. - 6:30 p.m.

**Registration/ Information Desk Hours**

*Location: Cedars/Pegasus/Whiterock Foyer*

### GENERAL SESSION

5:00 p.m. - 5:10 p.m.

**Welcome Address By The President**

President: Hugh Jones, BSc, MBChB, MD, FRCP(London), FRCP(Edinburgh)

5:10 p.m. - 5:20 p.m.

**Welcome Address and Housekeeping Remarks from Program Chair**

Speaker: Michael Zitzmann, MD, PhD, FRSM

5:20 p.m. - 5:30 p.m.

**Androgen Society Journal Update**

Speaker: Abraham Morgentaler, MD, FACS

5:30 p.m. - 6:30 p.m.

**Keynote Lecture: This Is Your Brain On Androgens**

Moderator: Abraham Morgentaler, MD, FACS

Speaker: James G. Pfaus, PhD, IF

6:30 p.m.

**Adjourn**

## FRIDAY, MARCH 03, 2023

### OVERVIEW

6:00 a.m. - 6:00 p.m.

**Registration/ Information Desk Hours**

*Location: Cedars/Pegasus/Whiterock Foyer*

7:00 a.m. - 8:00 a.m.

**Breakfast in the Exhibit Hall**

*Location: Plaza C*

7:00 a.m. - 4:00 p.m.

**Exhibit Hall Hours**

*Location: Plaza C*

12:10 p.m. - 1:10 p.m.

**Industry Sponsored Lunch Symposium**

*Location: Pegasus AB*

6:00 p.m. - 8:00 p.m.

**Welcome Reception in the Exhibit Hall**

*Location: Plaza C*

### GENERAL SESSION

8:00 a.m. - 9:30 a.m.

**Introducing Essentials in Men's Health Care**

Moderator: Michael Zitzmann, MD, PhD, FRSM

8:00 a.m. - 8:20 a.m.

**New Strategies and Horizons in Male Health Care**

Speaker: Martin Miner, MD

8:20 a.m. - 8:40 a.m.

**Choosing the Optimal Form of Testosterone Therapy For Each Patient**

Speaker: Omer Raheem, MD

8:40 a.m. - 9:00 a.m.

**How to Navigate Diagnostic Pathways in Modern Male Health Care**

Speaker: Adrian S. Dobs, MD, MHS

9:00 a.m. - 9:20 a.m.

**Sexual Function as a Gateway to Male Health**

Speaker: Wayne J. G. Hellstrom, MD, FACS

9:20 a.m. - 9:30 a.m.

**Discussion**

9:30 a.m. - 10:00 a.m.

**Break & Networking in the Exhibit Hall**

*Location: Plaza C*

10:00 a.m. - 11:50 a.m.

**The Diabetes Revolution and Testosterone**

Moderators: Adrian S. Dobs, MD, MHS

Martin Miner, MD

10:00 a.m. - 10:20 a.m.

**Why There Is A Paradigm Shift In Treatment Of Type 2 Diabetes**

Speaker: Paresh Dandona, MD



# Scientific Program

10:20 a.m. - 10:40 a.m.	<b>Testosterone and Obesity</b> Speaker: Farid Saad, DVM, PhD
10:40 a.m. - 11:00 a.m.	<b>The T4DM Study: Is There An Impact On Diabetes Care?</b> Speaker: Michael Zitzmann, MD, PhD, FRSM
11:00 a.m. - 11:20 a.m.	<b>Androgens and Insulin Resistance in T2Diabetes</b> Speaker: Hugh Jones, BSc, MBChB, MD, FRCP(London), FRCP(Edinburgh)
11:20 a.m. - 11:40 a.m.	<b>ABCD Worldwide Audit : What Is That?</b> Speakers: Hugh Jones, BSc, MBChB, MD, FRCP(London), FRCP(Edinburgh) Bob Ryder, MD
11:40 a.m. - 11:50 a.m.	<b>Discussion</b>
11:50 a.m. - 12:00 p.m.	<b>Lifetime Achievement Award</b> Moderator: Sandeep Dhindsa, MD Recipient: Paresh Dandona, MD
12:00 p.m. - 12:10 p.m.	<b>Dismiss for Lunch</b>
12:10 p.m. - 1:10 p.m.	<b>Industry Sponsored Lunch Symposium</b> <i>Location: Pegasus AB</i>
1:10 p.m. - 1:30 p.m.	<b>Abstract Session</b> ( <i>Link to full abstracts on page 10</i> )
1:10 p.m. - 1:15 p.m.	<b>#1 TESTOSTERONE BOOSTER SUPPLEMENTS SOLD ON AMAZON MARKETPLACE: IS THERE EVIDENCE SUPPORTING THEIR EFFICACY AND SAFETY?</b> Presenter: Danish Singh, MD
1:15 p.m. - 1:20 p.m.	<b>#2 COMPARISON OF EFFECTS OF LONG-TERM TESTOSTERONE THERAPY (TTh) ON SEXUAL AND URINARY FUNCTION AND QUALITY OF LIFE OVER 14 YEARS IN MEN WITH PRIMARY VS. FUNCTIONAL HYPOGONADISM</b> Presenter: Farid Saad, DVM, PhD
1:20 p.m. - 1:25 p.m.	<b>#3 COMPARISON OF EFFECTS OF LONG-TERM TESTOSTERONE THERAPY (TTh) ON LIPID PATTERN OVER 14 YEARS IN MEN WITH PRIMARY VS. FUNCTIONAL HYPOGONADISM</b> Presenter: Farid Saad, DVM, PhD
1:25 p.m. - 1:30 p.m.	<b>#4 COMPARISON OF EFFECTS OF LONG-TERM TESTOSTERONE THERAPY (TTh) ON ANTHROPOMETRIC MEASURES OVER 14 YEARS IN MEN WITH PRIMARY VS. FUNCTIONAL HYPOGONADISM</b> Presenter: Farid Saad, DVM, PhD
1:30 p.m. - 3:00 p.m.	<b>Androgens and Blood</b> Moderator: Janine David, MD, FECSM
1:30 p.m. - 1:50 p.m.	<b>The Association Between Low T and Anemia</b> Speaker: Jean P. Deslypere, MD, PhD
1:50 p.m. - 2:10 p.m.	<b>Anemia as a Cardiovascular Risk Factor in Men</b> Speaker: Jean P. Deslypere, MD, PhD
2:10 p.m. - 2:30 p.m.	<b>New Data: Testosterone Therapy and Hematocrit</b> Speaker: Michael Zitzmann, MD, PhD, FRSM
2:30 p.m. - 2:50 p.m.	<b>Anemia in Testosterone Deficiency and Polycythemia on Testosterone Therapy</b> Speaker: Sudarshan Ramachandran, PhD
2:50 p.m. - 3:00 p.m.	<b>Discussion</b>
3:00 p.m. - 3:30 p.m.	<b>Break &amp; Networking in the Exhibit Hall</b> <i>Location: Plaza C</i>
3:30 p.m. - 5:00 p.m.	<b>Androgens, Sexual, and Mental Health</b> Moderator: Michael Zitzmann, MD, PhD, FRSM
3:30 p.m. - 3:50 p.m.	<b>Testosterone and Quality of Life in Patients with Hypogonadism and Type 2 Diabetes</b> Speaker: Preethi Mohan Rao, MBBS, MRCP (London), CCST (Endocrinology), MD

# Scientific Program

3:50 p.m. - 4:10 p.m.	<b>Role of Testosterone and PDE5 Inhibitors in Acute COVID Infections</b> Speaker: Geoffrey Hackett, MD
4:10 p.m. - 4:30 p.m.	<b>Testosterone, Hypertension, and Mortality</b> Speaker: Sudarshan Ramachandran, PhD
4:30 p.m. - 4:50 p.m.	<b>British Society of Sexual Guidelines for Management of Testosterone Deficiency in Men</b> Speaker: Geoffrey Hackett, MD
4:50 p.m. - 5:00 p.m.	<b>Discussion</b>
5:00 p.m. - 6:00 p.m.	<b>The Endocrinology vs Urology Debate: Have We Been Too Cautious With T Therapy or Not ?</b> Moderator: Geoffrey Hackett, MD Debaters: Michael S. Irwig, MD Abraham Morgentaler, MD, FACS <i>Irwig-No; Morgentaler-Yes</i>
6:00 p.m. - 8:00 p.m.	<b>Welcome Reception in the Exhibit Hall</b> <i>Location: Plaza C</i>

## SATURDAY, MARCH 04, 2023

### OVERVIEW

6:00 a.m. - 5:00 p.m.	<b>Registration/ Information Desk Hours</b> <i>Location: Cedars/Pegasus/Whiterock Foyer</i>
7:00 a.m. - 8:00 a.m.	<b>Breakfast in the Exhibit Hall</b> <i>Location: Plaza C</i>
7:00 a.m. - 3:00 p.m.	<b>Exhibit Hall Hours</b> <i>Location: Plaza C</i>
8:00 a.m. - 8:20 a.m.	<b>Annual Business Meeting</b> <i>Location: Cedars/Pegasus/Whiterock Foyer</i>

### GENERAL SESSION

8:20 a.m. - 10:00 a.m.	<b>Safety of Testosterone Therapy</b> Moderator: Michael Zitzmann, MD, PhD, FRSM
8:20 a.m. - 8:40 a.m.	<b>Moving Forward With Testosterone Therapy In Men With Prostate Cancer</b> Speaker: Mohit Khera, MD, MBA, MPH
8:40 a.m. - 9:10 a.m.	<b>T and CVD and TRAVERSE Trial Update</b> Speaker: Mohit Khera, MD, MBA, MPH
9:10 a.m. - 9:30 a.m.	<b>Testosterone Deficiency, The Unrecognized Consequence of the Opioid Epidemic in Men</b> Speaker: Janine David, MD, FECSM
9:30 a.m. - 9:50 a.m.	<b>MACE, Angina and Cardiac Failure</b> Speaker: Hugh Jones, BSc, MBChB, MD, FRCP(London), FRCP(Edinburgh)
9:50 a.m. - 10:00 a.m.	<b>Discussion</b>
10:00 a.m. - 10:30 a.m.	<b>Break &amp; Networking in the Exhibit Hall</b> <i>Location: Plaza C</i>
10:30 a.m. - 11:00 a.m.	<b>Clinical Case Discussion</b> Moderator: Abraham Morgentaler, MD, FACS Panelists: Sandeep Dhindsa, MD Hugh Jones, BSc, MBChB, MD, FRCP(London), FRCP(Edinburgh) Mohit Khera, MD, MBA, MPH Michael Zitzmann, MD, PhD, FRSM
11:00 a.m. - 11:30 a.m.	<b>COVID-19 and Testosterone</b> Moderators: Janine David, MD, FECSM Geoffrey Hackett, MD Speaker: Sandeep Dhindsa, MD
11:30 a.m. - 12:30 p.m.	<b>Lunch in the Exhibit Hall</b> <i>Location: Plaza C</i>

# Scientific Program

12:30 p.m. - 12:40 p.m.	<b>Dedication to Education Award</b> Moderator: Abraham Morgentaler, MD, FACS Recipient: Larry Lipshultz, MD
12:40 p.m. - 1:00 p.m.	<b>Reduction Of Hormone Related Cancers Using Testosterone And Metformin</b> Moderator: Mohit Khera, MD, MBA, MPH Speaker: David S. Lopez, MS, MPH, DrPH
1:00 p.m. - 2:30 p.m.	<b>Assessment of T-Levels</b> Moderator: Sandeep Dhindsa, MD
1:00 p.m. - 1:20 p.m.	<b>Testing and Harmonization of Testosterone Levels In The UK</b> Speaker: Prof. Mark Livingston, PhD FRCPATH FRSC
1:20 p.m. - 1:40 p.m.	<b>What The Clinician Should Know About Testing For Total, Bioavailable, And Free Testosterone</b> Speaker: Ravinder Singh, PhD
1:40 p.m. - 2:00 p.m.	<b>Harmonization of Testosterone Levels by the Centers for Disease Control: Rationale and Practice</b> Speaker: Hubert Vesper, PhD
2:00 p.m. - 2:20 p.m.	<b>Clinical Application of Testosterone Tests and Reference Ranges</b> Speaker: Abraham Morgentaler, MD, FACS
2:20 p.m. - 2:30 p.m.	<b>Discussion</b>
2:30 p.m. - 3:00 p.m.	<b>Break &amp; Networking in the Exhibit Hall</b> <i>Location: Plaza C</i>
3:00 p.m. - 3:25 p.m.	<b>Abstract Session 2</b> <i>(Link to full abstracts on page 10)</i>
3:00 p.m. - 3:05 p.m.	<b>#5 WELLNESS AND PREVALENCE OF HYPOGONADISM AMONG MALE RESIDENT PHYSICIANS</b> Presenter: Chase W. Mallory, MD
3:05 p.m. - 3:10 p.m.	<b>#6 THE EFFECT OF TESTOSTERONE THERAPY UPON BONE REMODELLING IN TESTOSTERONE DEFICIENT APOE MICE FED A HIGH FAT DIET</b> Presenter: Daniel Kelly, PhD
3:10 p.m. - 3:15 p.m.	<b>#7 EFFECT OF TESTOSTERONE PELLET THERAPY ON BONE MINERAL DENSITY IN POSTMENOPAUSAL WOMEN</b> Presenter: Gayle Frazzetta, MD, FAAFP, CCD
3:15 p.m. - 3:20 p.m.	<b>#8 THE EFFICACY, SAFETY, AND OUTCOMES OF TESTOSTERONE USE AMONG TRANSGENDER MEN PATIENTS</b> Presenter: Omer Raheem, MD
3:20 p.m. - 3:25 p.m.	<b>#9 TESTOSTERONE THERAPY IN MEN WITH CLASSIC VS. FUNCTIONAL HYPOGONADISM: RESULTS FROM A CONTROLLED 9-YEAR, REAL-WORLD REGISTRY STUDY</b> Presenter: Michael Zitzmann, MD, PhD, FRSM
3:25 p.m. - 4:05 p.m.	<b>How I Use Testosterone Therapy In My Practice</b> Moderator: Abraham Morgentaler, MD, FACS
3:25 p.m. - 3:40 p.m.	Speaker: Rachel S. Rubin, MD
3:40 p.m. - 3:55 p.m.	Speaker: Gayle Frazzetta, MD, FAAFP, CCD
3:55 p.m. - 4:05 p.m.	<b>Discussion</b>
4:05 p.m. - 4:55 p.m.	<b>COVID, Testosterone, and the Immune System</b> Moderators: Hugh Jones, BSc, MBChB, MD, FRCP(London), FRCP(Edinburgh) Michael Zitzmann, MD, PhD, FRSM
4:05 p.m. - 4:25 p.m.	<b>Testosterone and the Immune System</b> Speaker: Daniel Kelly, PhD
4:25 p.m. - 4:45 p.m.	<b>Clinical Effect of Testosterone on Covid</b> Speaker: Sandeep Dhindsa, MD
4:45 p.m. - 4:55 p.m.	<b>Discussion</b>
4:55 p.m. - 5:00 p.m.	<b>Closing Remarks</b> President: Hugh Jones, BSc, MBChB, MD, FRCP(London), FRCP(Edinburgh)

# Speaker Biosketches



*Speaker biosketches are available online and can be accessed through the QR code or the link below.*

[tinyurl.com/ANDRO2023-Speakers](https://tinyurl.com/ANDRO2023-Speakers)

# Abstracts



*Full abstracts are available online and can be accessed through the QR code or the link below.*

[tinyurl.com/ANDRO2023-Abstracts](https://tinyurl.com/ANDRO2023-Abstracts)

## A decorative geometric pattern composed of various shades of blue, green, and grey triangles and hexagons, arranged in a complex, overlapping layout. The pattern is located on the right side of the page, partially overlapping the text area.

# Notes

[illegible]

# Industry Support

## Thank You to Our 2023 Promotional Partners

### Platinum Level



Andrology Research Academy



Innovating for Well-being

### Gold Level



## Thank You to Our 2023 Exhibitors

Ascend Therapeutics LLS


Endo Pharmaceuticals

Myovant Sciences, Inc.

Revive RX Pharmacy

TOLMAR Pharmaceuticals

# Exhibit Hall Floor Plan



Company Name	Table #
Ascend Therapeutics LLS	4
Endo Pharmaceuticals	1
Myovant Sciences, Inc.	2
Revive RX Pharmacy	3
TOLMAR Pharmaceuticals	5





# Androgen Society

**The Androgen Society**

Two Woodfield Lake  
1100 E. Woodfield Road, Suite 350  
Schaumburg, IL 60173

**(847) 517-7225**

**Contact@androgensociety.org**